Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation. Our choice today is a new addition to our overflowing pantry — hazelnut mocha. As always, you are invited to join us. Meanwhile, we have once again assembled a few items of interest for you. Best of luck on your journey today and, of course, do keep in touch. …
The U.S. Federal Trade Commission wants more information on a $16.5 million deal in which Novo Nordisk’s parent company would purchase Catalent, a contract drug manufacturer, weeks after an application to the regulator was refiled for approval of the deal, Reuters notes. Catalent said the companies were in the process of gathering information to respond to the agency request, which was received on May 2. In February, Novo Holdings agreed to buy Catalent to boost output of the popular Wegovy weight loss drug, and it would sell three of Catalent’s fill-finish sites for $11 billion to Novo Nordisk, which has struggled to meet demand for its drug.
A battle between the Arkansas Insurance Department and AstraZeneca is heating up with an August hearing scheduled to consider penalties against the company, which filed a lawsuit against the state earlier this year over a law known as the 340B Drug Pricing Nondiscrimination Act, The Arkansas Democrat-Gazette reports. The hearing will consider sanctions against AstraZeneca over its refusal to make its drugs discounted under 340B available to more than one contract pharmacy per covered entity. That refusal violates the state law, which went into effect in 2021. In 2023, AstraZeneca adopted a policy that recognizes only one contract pharmacy location for each 340B covered entity.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.